Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)

被引：7

作者：

Loibl, S. ^{[1
]}

Loirat, D. ^{[2
,3
]}

Tolaney, S. M. ^{[4
]}

Punie, K. ^{[5
,6
]}

Oliveira, M. ^{[7
,8
,9
]}

Rugo, H. S. ^{[10
]}

Bardia, A. ^{[11
]}

Hurvitz, S. A. ^{[12
]}

Brufsky, A. ^{[13
,14
]}

Kalinsky, K. ^{[15
]}

Cortes, J. ^{[16
]}

O'Shaughnessy, J. ^{[17
]}

Dieras, V. C. ^{[18
]}

Carey, L. A. ^{[19
]}

Gianni, L. ^{[20
]}

Gharaibeh, M. ^{[21
]}

Moore, L. ^{[21
]}

Shi, L. ^{[22
]}

Piccart, M. ^{[23
,24
]}

机构：

[1] Hamatol Onkol Gemeinschaftspraxis Bethanien Krank, Dept Med & Res, Frankfurt, Germany

[2] Inst Curie, Med Oncol Dept, Paris, France

[3] Inst Curie, D3i, Paris, France

[4] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA

[5] Univ Hosp Leuven, Leuven Canc Inst, Dept Gen Med Oncol, Leuven, Belgium

[6] Univ Hosp Leuven, Leuven Canc Inst, Multidisciplinary Breast Ctr, Leuven, Belgium

[7] Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain

[8] Vall dHebron Univ Hosp, Breast Canc Grp, Barcelona, Spain

[9] Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[10] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[11] Harvard Med Sch, Dept Hematol & Oncol, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA

[12] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Med Oncol,Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA

[13] Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Div Hematol Oncol, Pittsburgh, PA 15213 USA

[14] Univ Pittsburgh, Hillman Canc Ctr, Med Ctr, Pittsburgh, PA USA

[15] Columbia Univ Irving Med Ctr, Dept Med, New York, NY USA

[16] Quiron Grp, Med Oncol Dept, Int Breast Canc Ctr, Barcelona, Spain

[17] Texas Oncol Baylor A Charles Sammons Canc Ctr, Med Oncol, Dallas, TX USA

[18] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France

[19] Univ N Carolina, Med Hematol Oncol Div, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[20] Gianni Bonadonna Fdn, Med Oncol, Milan, Italy

[21] Gilead Sci Inc, Dept Global Value & Access, Morris Plains, NJ USA

[22] Evidera PPD, Dept Evidence Synth Modeling & Commun EMC, Waltham, MA USA

[23] Inst Jules Bordet, Med Oncol Dept, Brussels, Belgium

[24] Univ Libre Bruxelles, Brussels, Belgium

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.540

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

257P

引用

页码：S472 / S473

页数：2

共 50 条

[41] Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
Maltoni, Roberta
Bravaccini, Sara
ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (07)
[42] ASCENT-03: Phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC)
Bardia, A.
Punie, K.
Barrios, C. H.
Schneeweiss, A.
Zhai, X.
Huynh, D. H.
Vaksman, N.
Lai, C.
Tolaney, S. M.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S663 - S664
[43] Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis
Carey, Lisa A.
Loirat, Delphine
Punie, Kevin
Bardia, Aditya
Dieras, Veronique
Dalenc, Florence
Diamond, Jennifer R.
Fontaine, Christel
Wang, Grace
Rugo, Hope S.
Hurvitz, Sara A.
Kalinsky, Kevin
O'Shaughnessy, Joyce
Loibl, Sibylle
Gianni, Luca
Piccart, Martine
Zhu, Yanni
Delaney, Rosemary
Phan, See
Cortes, Javier
NPJ BREAST CANCER, 2022, 8 (01)
[44] Sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.
Bardia, Aditya
Tolaney, Sara M.
Loirat, Delphine
Punie, Kevin
Oliveira, Mafalda
Rugo, Hope S.
Brufsky, Adam
Kalinsky, Kevin
Cortes, Javier
O'Shaughnessy, Joyce
Dieras, Veronique C.
Carey, Lisa A.
Gianni, Luca
Piccart-Gebhart, Martine J.
Loibl, Sibylle
Zhu, Yanni
Phan, See-Chun
Hurvitz, Sara A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[45] An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
Cheng, Shao-Xian
Chen, Qiu-Chi
Lin, Guo-He
Han, Yan-Hong
Wang, Bi-Cheng
Dai, Yi
Zhao, Yan-Xia
MEDICINE, 2023, 102 (30) : E34486
[46] Metastatic triple-negative Breast Cancer (mTNBC) - Second-line Therapy mTNBC: Sacituzumab Govitecan with high Effectiveness even in HER2-low
不详
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (7-8) : 343 - 343
[47] Sacituzumab govitecan in Japanese patients with metastatic triple-negative breast cancer: phase 2 results of ASCENT J02
Naito, Y.
Nakamura, S.
Kawaguchi, N.
Ishida, T.
Nakayama, T.
Yamamoto, Y.
Masuda, N.
Matsumoto, K.
Kogawa, T.
Sudo, K.
Shimomura, A.
Lai, C.
Zhang, D.
Iwahori, Y.
Gary, D.
Huynh, D.
Iwata, H.
ANNALS OF ONCOLOGY, 2024, 35 : S1326 - S1326
[48] Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study
Abelman, Rachel Occhiogrosso
Spring, Laura
Niemierko, Andrzej
Abraham, Elizabeth
McNeice, Mary
Goff, Jennifer
Valenti, Amanda
Wander, Seth Andrew
Isakoff, Steven J.
Moy, Beverly
Juric, Dejan
Vidula, Neelima
Waks, Adrienne Gropper
Parsons, Heather Anne
Ellisen, Leif W.
Tolaney, Sara M.
Bardia, Aditya
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[49] Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer (vol 10, 33, 2024)
Hurvitz, Sara A.
Bardia, Aditya
Punie, Kevin
Kalinsky, Kevin
Carey, Lisa A.
Rugo, Hope S.
Dieras, Veronique
Phan, See
Delaney, Rosemary
Zhu, Yanni
Tolaney, Sara M.
NPJ BREAST CANCER, 2024, 10 (01)
[50] Real-world outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) in 2L+in the United States (US)
Kalinsky, Kevin
Spring, Laura
Yam, Clinton
Taylor, Aliki
Sjekloca, Nikoleta
Kaushiva, Alpana
Lai, Catherine
Ntalla, Ioanna
Nanda, Rita
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →